Publication | Closed Access

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

Antiviral CompoundNeurovirologyImmunologyAntiviral Drug DevelopmentHepatitisVirologyDuring 3-Day MonotherapyAntiviral TherapyPharmacotherapyAntiviral DrugTreatment-naive SubjectsMedicineRadiation Oncology